– Achieved Second Quarter 2023 Total Revenue of $37.6 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.5 Million – – Maintains Full Year 2023.
ABC News(NEW YORK) As the popularity of weight-loss drugs like Ozempic, Wegovy and Mounjaro continues to grow, some women are taking a closer look at whether the drugs could impact their chances of becoming pregnant.
Wynter Mitchell-Rohrbaugh told ABC News Good Morning America that she and her husband previously suffered four pregnancy losses in their quest to have a child. When the couple decided to turn to in-vitro fertilization, or IVF, Mitchell-Rohrbaugh said they hit another roadblock when a doctor told her she needed to lose 40 pounds before they could begin the process.
"I just kept thinking to myself, are you insane? I m not a small person," she said. "I m a plus-size woman."
For help losing the weight, Mitchell-Rohrbaugh said she turned to Ozempic, one of a class of drugs called GLP-1 RAs that help people produce insulin and lower the amount of sugar in the blood. The drugs work by slowing down movement of food through the stomach and curbing appetite
(NEW YORK) As the popularity of weight-loss drugs like Ozempic, Wegovy and Mounjaro continues to grow, some women are taking a closer look at whether the drugs could impact their chances of becoming pregnant. Wynter Mitchell-Rohrbaugh told ABC News' Good Morning America that she and her husband previously suffered four pregnancy losses in their